NanosonicsNNCSF 88 Debt-to-EBITDA is 0.22 as of Dec. 2025, which is 10% above its 10-year median of 0.20. GuruFocus rates NNCSF with a GF Score™ of 88/100 and a GF Value™ of $3.51 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 468 Medical Devices & Instruments companies, Nanosonics ranks better than 82.48% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nanosonics's Debt-to-EBITDA or its related term are showing as below:
NNCSF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.2 Max: 1.49
Current: 0.21
During the past 13 years, the highest Debt-to-EBITDA Ratio of Nanosonics was 1.49. The lowest was 0.03. And the median was 0.20.
NNCSF's Debt-to-EBITDA is ranked better than 82.48% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs NNCSF: 0.21
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nanosonics Debt-to-EBITDA Related Terms
Nanosonics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nanosonics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNCSF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Nanosonics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nanosonics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Nanosonics (NNCSF) has a Debt-to-EBITDA of 0.22 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nanosonics. This is 10% above median its historical median of 0.20. Over the past decade, Nanosonics' Debt-to-EBITDA has ranged from 0.03 to 1.49. According to the industry distribution chart, Nanosonics ranks #82 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 17.5%.
Is Nanosonics' Debt-to-EBITDA too high?
Nanosonics' current Debt-to-EBITDA of 0.22 is 10% above median its 10-year median of 0.20. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 1.49. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.56. Nanosonics' value of 0.22 is 85.9% below this industry median. Based on the distribution chart, Nanosonics ranks #82 out of 468 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nanosonics has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #82 out of 468 companies for Debt-to-EBITDA. This places Nanosonics in the top 18% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.56. Nanosonics' value of 0.22 is 85.9% below this benchmark. Historically, Nanosonics' own Debt-to-EBITDA has ranged from 0.03 to 1.49 over the past decade. While the company's 10-year median is 0.20 vs. the industry median of 1.56, Nanosonics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current Debt-to-EBITDA of 0.22 is 85.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nanosonics. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current Debt-to-EBITDA is 0.22, which is 10% above median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.51, compared to a current price of $2.55 — trading 27.4% below its estimated fair value. The current Debt-to-EBITDA is 0.22, which is 10% above median its 10-year median of 0.20 and 85.9% below the Medical Devices & Instruments industry median of 1.56. Nanosonics' overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nanosonics (NNCSF), the current Debt-to-EBITDA is 0.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.55 is trading 27.4% below its estimated GF Value™ of $3.51.
GuruFocus considers Nanosonics to be Modestly Undervalued.
Key valuation signals for NNCSF:
Debt-to-EBITDA: 0.22 (10% above median its 10-year median of 0.20)
GF Value™: $3.51 vs. price of $2.55 (27.4% below fair value)
Industry Position: 85.9% below the Medical Devices & Instruments median (#82 of 468)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
88GF Score
Get the complete analysis for NNCSF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
